Literature DB >> 11096488

Chronic Heart Failure.

.   

Abstract

Physicians must aggressively treat heart failure in the early stages to prevent disease progression and improve survival. Early treatment implies early diagnosis of left ventricular (LV) dysfunction, before the onset of symptoms. Patients with risk factors for the development of heart failure, especially coronary disease or hypertension, should undergo echocardiography to evaluate LV function. Patients with LV systolic dysfunction should be further evaluated to determine the type of cardiac dysfunction, uncover correctable etiologic factors, determine prognosis, and guide treatment. Angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking drugs improve survival and are integral to the treatment plan. Physicians should prescribe an ACE inhibitor as initial therapy for all patients with LV systolic dysfunction unless there are specific contraindications. The combination of hydralazine and isosorbide dinitrate is an acceptable alternative therapy for patients who cannot take ACE inhibitors. Diuretics should be used if there are signs or symptoms of volume overload. Beta-adrenergic blocking drugs should be added to therapy in stable patients with mild to moderate heart failure after optimal treatment with ACE inhibitors, diuretics, or other vasodilators. Digoxin should be used routinely in patients with severe heart failure and should be added to therapy in patients with mild to moderate heart failure who remain symptomatic despite optimal doses of ACE inhibitors and diuretics. Spironolactone should be added, but electrolytes should be closely monitored. Warfarin anticoagulation should be considered in patients with a left ventricular ejection fraction (LVEF) of 35% or less. Until survival data exist, angiotensin receptor blockers (ARBs) should not be used as initial therapy or as sole therapy but can be used for ACE-intolerant patients or can be added to standard heart failure therapy. Outpatient use of intravenous inotropic therapy should be avoided. Patients with severe heart failure should have peak oxygen consumption measured to quantify functional impairment, determine prognosis, and identify the need for advanced heart failure therapy. Patients who remain symptomatic while receiving optimal standard therapy should be referred early to a specialized heart failure center.

Entities:  

Year:  1999        PMID: 11096488     DOI: 10.1007/s11936-999-0039-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  22 in total

1.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials.

Authors:  P A Heidenreich; T T Lee; B M Massie
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

3.  The effect of digoxin on mortality and morbidity in patients with heart failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-20       Impact factor: 91.245

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

5.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

6.  Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction.

Authors:  A S Al-Khadra; D N Salem; W M Rand; J E Udelson; J J Smith; M A Konstam
Journal:  J Am Coll Cardiol       Date:  1998-03-15       Impact factor: 24.094

7.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Authors:  B Pitt; R Segal; F A Martinez; G Meurers; A J Cowley; I Thomas; P C Deedwania; D E Ney; D B Snavely; P I Chang
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

8.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.

Authors:  B F Uretsky; J B Young; F E Shahidi; L G Yellen; M C Harrison; M K Jolly
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).

Authors: 
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

View more
  2 in total

1.  Myocarditis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

2.  Myocarditis.

Authors:  Elaine Winkel; Joseph Parrillo
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.